Martin Haluzík/LinkedIn
Nov 23, 2025, 14:36
Martin Haluzík: Excellent Review on PCSK-9 Inhibitors Just Published in AJPC
Martin Haluzík, Professor of Medicine at Institute for Clinical and Experimental Medicine, shared a post on LinkedIn:
“The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
Excellent review on PCSK-9 inhibitors just published in American Journal of Preventive Cardiology (AJPC) Alexander Razavi and Michael Shapiro.
Title: The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease
Authors: Alexander C. Razavi, Michael D. Shapiro
Read full study here.
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important component in the regulation of low-density lipoprotein-cholesterol (LDL-C) metabolism, discovered more than two decades ago.
- The discovery of PCSK9 and subsequent development of PCSK9 inhibitors (PCSK9i) have helped usher a new era of non-statin lipid-lowering therapy for atherosclerotic cardiovascular disease (ASCVD) risk reduction.
- In addition to individuals with clinical ASCVD, there have been evolving recommendations for the clinical use of PCSK9i to extend to individuals with familial hypercholesterolemia as well as high-risk primary prevention patients, including those with advanced subclinical atherosclerosis.
- Beyond the initial development of PCSK9 monoclonal antibodies (mAb), this class of therapies has expanded to include several different modes of administration that are currently being studied for efficacy and safety, including small interfering RNA (siRNA), adnectins, oral, and potentially even CRISPR-based methods.
- Such scientific advancement and enthusiasm have been moderated by public health challenges involving cost and access of therapy. In this review, the authors summarize PCSK9 biology, followed by an assessment of completed and ongoing randomized controlled trials involving PCSK9i along with a review of current clinical recommendations for the utilization of PCSK9i, future directions, and concluded with clinical and public health impact.
- Very comprehensive and well written review
- Excellent summary of future directions
- The develompment of oral PCSK-9 inhibitors with similar efficacy as injectables such as enlicitide these developments may shift CV complications prevention to a completely different level
Excellent paper! Congratulations to the authors!”
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 18:22Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
-
Apr 10, 2026, 17:59Michelle Leona Cecil: Representing Microhealth at The Coalition for Hemophilia B Annual Symposium
-
Apr 10, 2026, 17:47Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
-
Apr 10, 2026, 17:39Diverse Voices But Shared Mission – Day 1 of EHC Youth Leadership Workshop
-
Apr 10, 2026, 17:30Make Your Mark at the World Stroke Congress 2026 – World Stroke Organization
-
Apr 10, 2026, 17:23Sofie Abels: Implications for Targeted Screening for Thrombophilia in Young Stroke Patients
-
Apr 10, 2026, 17:08Armghan Ans: 3 Questions Worth Sitting with If You Work in Stroke AI
-
Apr 10, 2026, 17:03William Wallace: Vitamin C Is More Than ”Immune Support”
-
Apr 10, 2026, 16:58Wolfgang Miesbach: Greater Symptom Burden in Women with Bleeding Disorders – Insights from Irish Data